What does ruxolitinib/ruxolitinib cream do?

Ruxolitinib is a topical JAK inhibitor that has attracted much attention in the field of dermatology treatment in recent years. It mainly interferes with the local inflammatory response and immune abnormalities in the skin by inhibiting the Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) signaling pathways, thereby exerting a therapeutic effect on atopic dermatitis (AD) and vitiligo. Unlike traditional corticosteroids or calcineurin inhibitors, ruxolitinib cream stands out among topical drugs because of its more targeted nature, lower systemic absorption rate, and lower hormone-related side effects, and is regarded as an innovative means of immunomodulation.

The mechanism of action of ruxolitinib cream is mainly reflected in the precise suppression of local immune and inflammatory signals in the skin. The JAK-STAT pathway is an important pathway for regulating cytokine release and inflammatory cell activation, and plays a key role in the pathological mechanisms of various skin diseases. Topical application of ruxolitinib cream can effectively reduce typical symptoms such as itching, erythema, and depigmentation. It shows good tolerance and safety, especially for patients with mild to moderate atopic dermatitis and patients with non-segmental vitiligo. With the approval of the FDA and multinational drug regulatory agencies, the drug has been recommended as a treatment alternative for certain populations who cannot use steroids or other immunomodulators for a long time.

It is worth noting that ruxolitinib cream has dual indications and is one of the few topical drugs approved for use in both atopic dermatitis and vitiligo. Its skin absorption is mainly localized and rarely causes systemic immunosuppression. Without damaging the skin barrier, it can accurately target inflammatory lesions and reduce the impact on healthy skin. As a result, it has been included on an increasing number of dermatologists’ list of preferred treatments.

Reference: https://www.opzelura.com/